Amneal Pharmaceuticals Reports Strong Q3 2026 Results and Raises Full-Year Guidance
Amneal Pharmaceuticals (AMRX) delivered a robust third quarter in 2026, reporting net revenue of $862.7 million, a 10% increase year-over-year. Growth was primarily driven by the specialty segment, which rose 20% due to the adoption of CREXONT and BREKIYA brands, and affordable medicines, which grew 19%. Adjusted EBITDA saw significant expansion, rising 30% to $207 million, while adjusted diluted EPS increased 53% to $0.26. Following these strong results, management raised its full-year guidance for revenue, adjusted EBITDA, and adjusted EPS. However, operating cash flow guidance was revised downward to a range of $325 million to $375 million due to strategic inventory building and timing of collections. Despite a temporary operational disruption at an India facility caused by flooding in July, the company maintains long-term growth targets, aiming for revenue between $4.3 billion and $4.5 billion by 2030.
Tickers: $AMRX
Topics: EBITDA EPS financial guidance product launch revenue growth